Yang M, Hlady RA, Zhou D, et al. - For advanced-stage type 2 papillary renal cell carcinoma (PRCC), researchers wanted to find possible DNA methylation-based markers and treatment targets. They found four CpGs (cg00489401, cg27649239, cg20555674, and cg07196505) that may serve as DNA methylation markers for discriminating localized from advanced-stage type 2 PRCC through analysis of 450K methylation data from The Cancer Genome Atlas-kidney renal papillary cell carcinoma. According to findings, DNA methylation markers that distinguish between localized and advanced stage type 2 PRCC can be valuable markers for disease staging or outcome, and PTK7 copy gain may be a target for advanced stage type 2 PRCC treatment. In patients with PRCC, stepwise methylation changes and copy number gain are also linked to disease stage.